Results 121 to 130 of about 23,087 (229)

Effect of denosumab on the incidence of fractures and mortality in patients undergoing hemodialysis: A retrospective cohort study.

PLoS ONE
BackgroundPatients undergoing hemodialysis are at an elevated risk of fractures; however, substantial evidence for osteoporosis treatment in this population is lacking.
Arisa Kobayashi, Tatsuhiro Yaginuma, Kazuhiko Kato, Akio Nakashima, Ichiro Ohkido, Takashi Yokoo   +5 more
doaj   +1 more source

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis

, 2018
Takako Suzuki,1 Yukio Nakamura,1,2 Hiroyuki Kato1 1Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan; 2Department of Orthopaedic Surgery, Showa Inan General Hospital, Komagane, Japan Background: This 3-year ...
Kato H, Suzuki T, Nakamura Y
core  

Injectable Zein‐Based Photothermal Composite Hydrogel Enhances Osteoporotic Tendon–Bone Healing

Small Methods, Volume 10, Issue 17, 9 September 2026.
Schematic illustration of the Zein‐based, dopamine‐grafted, niacin‐loaded carbon nanosphere (ZDC) composite hydrogel for enhancing healing of osteoporotic rotator cuff tears. This electron beam‐modified composite hydrogel is designed for NIR‐responsive release of niacin, which alleviates inflammation, promotes angiogenesis, and facilitates the ...
Kai Ye, Peng Ding, Zhenyou Dong, Wenyan Shi, Longxiang Shen, Xianyou Zheng   +5 more
wiley   +1 more source

Efficacy of denosumab therapy for neurofibromatosis type I with osteoporosis and history of fractures: a case report

, 2018
Masashi Uehara,1 Yukio Nakamura,1 Jun Takahashi,1 Mikio Kamimura,2 Fumihiro Isobe,1 Tomomi Yamaguchi,3,4 Tomoki Kosho,3,4 Shigeharu Uchiyama,1,5 Takako Suzuki,1 Hiroyuki Kato1 1Department of Orthopedic Surgery, Shinshu University School of Medicine ...
Kamimura M, Isobe F, Kato H, Suzuki T, Yamaguchi T, Nakamura Y, Uehara M, Kosho T, Uchiyama S, Takahashi J   +9 more
core  

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

Acta Ophthalmologica, Volume 104, Issue 6, Page e630-e647, September 2026.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen, Jari Haukka, Tuomas Lilius, Sirpa Loukovaara   +3 more
wiley   +1 more source

Giant-cell tumor of bone: treatment options and role of denosumab

, 2015
Arun S Singh,1 Neal S Chawla,2 Sant P Chawla2 1Sarcoma Service, Division of Hematology/Oncology, University of California, Los Angeles, 2Sarcoma Oncology Center, Santa Monica, CA, USA Abstract: Giant-cell tumor of bone is a rare, locally aggressive ...
Chawla SP, Singh AS, Chawla NS
core  

Computer simulation-based modeling of the pharmaceutical intervention of postmenopausal osteoporosis by denosumab

, 2012
Postmenopausal osteoporosis (PMO), leading to a higher bone fracture risk, is characterized by a significantly increasing bone porosity. Recently, denosumab, which is able to efficiently interfere with bone resorption, has been approved for the treatment
Pivonka, P., Scheiner, S., Smith, D. W., Stefan Scheiner, Dunstan, C. R., Colin R. Dunstan, David W. Smith, Peter Pivonka   +7 more
core   +1 more source

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers

British Journal of Haematology, Volume 209, Issue 3, Page 1076-1084, September 2026.
Summary The Magnolia study demonstrated that continuation of zoledronic acid (ZOL) beyond 2 years reduces the risk of progressive bone disease (PBD) in patients with multiple myeloma (MM). This follow‐up study investigated the effects of ZOL in patients achieving very good partial response (VGPR) compared to patients who did not and whether bone ...
Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jonna Skov Madsen, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Aneta Alexandra Nielsen, Dorte Aalund Olsen, Kent Søe, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold, Thomas Lund   +17 more
wiley   +1 more source

JMT103 versus Non‐Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score‐Matched Comparison

Cancer Medicine
Background Giant cell tumors of bone (GCTB) are RANK/RANK‐ligand positive, progressive osteolytic tumors. There was no medical treatment for GCTB based on efficacy and safety data from Chinese patients.
Hairong Xu, Yong Zhou, Feng Wei, Yi Ding, Huachao Shan, Yongkun Yang, Weifeng Liu, Tao Jin, Yi Luo, Fan Tang, Minxun Lu, Xin He, Wenli Zhang, Shaomin Yang, Lihua Zhang, Juan Wang, Hong Li, Chongqi Tu, Xiaohui Niu   +18 more
doaj   +1 more source

Expanding Spectrum of FIG4‐Related Neurological Disorders of Lysosomal Homeostasis: Case Report and Overview of the Potential Genotype–Phenotype Correlations

Clinical Genetics, Volume 110, Issue 3, Page 363-368, September 2026.
FIG4 is essential for lysosomal homeostasis. FIG4‐related disorders present as a continuous spectrum from the juvenile lethality in Yunis‐Varon syndrome to an increased risk of amyotrophic lateral sclerosis (ALS) in adult life. FIG4‐related disorders comprise a novel group of disorders of lysosomal homeostasis and can be classified into severe ...
Pankaj Prasun, Matthew Rasberry
wiley   +1 more source